文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

经鼻高流量氧疗对肥胖患者镇静胃肠镜低氧发生率的影响:多中心随机对照试验

Effect of high flow nasal cannula oxygenation on incidence of hypoxia during sedated gastrointestinal endoscopy in patients with obesity: multicentre randomised controlled trial.
PubMed 文献 · BMJ · 2025-02-11
一句话结论肥胖患者镇静胃肠镜时,经鼻高流量氧疗较普通鼻导管显著降低低氧(2.0% vs 21.2%)、亚临床呼吸抑制和重度低氧发生率,且不增加其他不良事件。

该多中心随机平行对照试验纳入上海3家三级医院的1000例肥胖(BMI≥28)成人患者,随机接受普通鼻导管或经鼻高流量氧疗(HFNC),在丙泊酚联合低剂量舒芬太尼镇静下完成胃肠镜。984例完成分析,HFNC组低氧发生率2.0%(10/497)显著低于普通鼻导管组21.2%(103/487),差值-19.14(95%CI -23.09至-15.36,P<0.001);亚临床呼吸抑制5.6% vs 36.3%,重度低氧0% vs 4.1%,均P<0.001。其他镇静相关不良事件两组无差异。结论提示肥胖患者镇静胃肠镜时HFNC可显著降低低氧相关事件。

要点

  • 肥胖(BMI≥28)患者镇静胃肠镜时,HFNC组低氧(75%≤SpO2<90%且<60秒)发生率2.0%(10/497) vs 普通鼻导管21.2%(103/487),差值-19.14(95%CI -23.09至-15.36,P<0.001)。
  • HFNC组亚临床呼吸抑制(90%≤SpO2<95%任意时长)5.6%(28/497) vs 普通鼻导管36.3%(177/487),差值-30.71(95%CI -35.40至-25.92,P<0.001)。
  • HFNC组重度低氧(SpO2<75%任意时长或75%≤SpO2<90%且>60秒)0%(0/497) vs 普通鼻导管4.1%(20/487),差值-4.11%(95%CI -6.26至-2.48,P<0.001)。
  • 其他镇静相关不良事件两组无差异。
  • 研究为多中心随机对照试验,纳入1000例肥胖成人,984例完成分析,镇静方案为丙泊酚联合低剂量舒芬太尼。

适用人群与场景

  • 纳入标准:肥胖(体重指数≥28)的成人患者,计划接受胃肠镜。
  • 场景:上海3家三级医院,镇静胃肠镜操作过程中。

诊断标准与关键阈值

  • 低氧定义:75%≤SpO2<90%且持续时间<60秒。
  • 亚临床呼吸抑制定义:90%≤SpO2<95%,任意持续时间。
  • 重度低氧定义:SpO2<75%任意持续时间,或75%≤SpO2<90%且持续时间>60秒。

处置流程与药物剂量

  • 镇静方案:丙泊酚联合低剂量舒芬太尼。
  • 干预:经鼻高流量氧疗(HFNC)或普通鼻导管给氧,均在镇静操作期间使用。

研究设计与关键结果

  • 研究类型:多中心、随机、平行组试验;2021年5月6日至2023年5月26日纳入1000例,984例完成分析(平均年龄49.2岁;女性36.9%,n=363)。
  • 主要终点:低氧发生率HFNC组2.0%(10/497) vs 普通鼻导管组21.2%(103/487),差值-19.14(95%CI -23.09至-15.36;P<0.001)。
  • 次要终点:亚临床呼吸抑制HFNC组5.6%(28/497) vs 普通鼻导管组36.3%(177/487),差值-30.71(95%CI -35.40至-25.92;P<0.001)。
  • 次要终点:重度低氧HFNC组0%(0/497) vs 普通鼻导管组4.1%(20/487),差值-4.11%(95%CI -6.26至-2.48;P<0.001)。
  • 其他镇静相关不良事件两组无差异。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对肥胖(体重指数≥28)患者行丙泊酚联合低剂量舒芬太尼镇静胃肠镜时,使用HFNC较普通鼻导管可显著降低低氧、亚临床呼吸抑制和重度低氧的发生率,且不增加其他不良事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine whether high flow nasal cannula (HFNC) oxygenation can reduce the incidence of hypoxia during sedated gastrointestinal endoscopy in patients with obesity.

DESIGN: Multicentre, randomised, parallel group trial.

SETTING: Three tertiary hospitals in Shanghai, China.

PARTICIPANTS: 1000 adult patients with obesity (body mass index ≥28) who were scheduled for gastrointestinal endoscopy.

INTERVENTIONS: Participants were randomly allocated to receive regular nasal cannula oxygenation or HFNC oxygenation during a sedated procedure with propofol and low dose sufentanil.

MAIN OUTCOME MEASURES: The primary outcome was the incidence of hypoxia (75%≤SpO2<90% for <60 s) during the procedure. Secondary outcomes included the incidences of subclinical respiratory depression (90%≤SpO2<95% for any duration) and severe hypoxia (SpO2<75% for any duration or 75%≤SPO2<90% for >60 s) during the procedure.

RESULTS: From 6 May 2021 to 26 May 2023, 984 patients (mean age 49.2 years; 36.9% (n=363) female) completed the study and were analysed. Compared with regular nasal cannula oxygenation, HFNC oxygenation reduced the incidence of hypoxia from 21.2% (103/487) to 2.0% (10/497) (difference -19.14, 95% confidence interval -23.09 to -15.36; P<0.001), subclinical respiratory depression from 36.3% (177/487) to 5.6% (28/497) (difference -30.71, -35.40 to -25.92; P<0.001), and severe hypoxia from 4.1% (20/487) to 0% (0/497) (difference -4.11%, -6.26 to -2.48; P<0.001). Other sedation related adverse events did not differ between the two groups.

CONCLUSIONS: In patients with obesity, oxygenation via HFNC during sedated gastrointestinal endoscopy significantly reduced the incidences of hypoxia, subclinical respiratory depression, and severe hypoxia without increasing other adverse events.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04500392.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Wang L, Zhang Y, Han D, et al. Effect of high flow nasal cannula oxygenation on incidence of hypoxia during sedated gastrointestinal endoscopy in patients with obesity: multicentre randomised controlled trial. BMJ. 2025. PMID: 39933757. doi:10.1136/bmj-2024-080795

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。